Radioimmunoimaging diagnosis of human bladder carcinoma.
The monoclonal antibody (BDI-1) against human bladder carcinoma has been shown to have selective reactivity for bladder cancer. A total of 19 bladder cancer patients were studied by radioimmunoimaging (RII) and a clear immunoscintigraphy was observed in all. Blood samples collected at 1, 2, 3, days after instillation were shown to be almost free from radioactivity. It is suggested that BDI-1, as a target carrier, might also be for instillation target treatment of superficial bladder cancer.
Yu
L Z
LZ
Department of Immunology, Beijing Medical University, China.
Gu
F L
FL
Zhang
C L
CL
D000818:Animals; D000911:Antibodies, Monoclonal; D002295:Carcinoma, Transitional Cell / Q000000981:diagnostic imaging; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D016719:Radioimmunodetection; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging*
D000911:Antibodies, Monoclonal